{"id":"levodopa-dispersible","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Nausea"},{"rate":"20-40","effect":"Dyskinesia"},{"rate":"10-20","effect":"Orthostatic hypotension"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-15","effect":"Hallucinations"},{"rate":"5-10","effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levodopa (L-DOPA) is a precursor amino acid that crosses the blood-brain barrier and is enzymatically converted to dopamine by aromatic amino acid decarboxylase. This restores dopamine neurotransmission in the basal ganglia, alleviating motor symptoms of Parkinson's disease. The dispersible formulation allows faster absorption and onset of action compared to standard tablets.","oneSentence":"Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:59.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease (motor symptoms)"}]},"trialDetails":[{"nctId":"NCT02769793","phase":"PHASE4","title":"Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2015-06","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT02680977","phase":"PHASE2","title":"Mucuna Pruriens Therapy in Parkinson's Disease","status":"COMPLETED","sponsor":"ASST Gaetano Pini-CTO","startDate":"2016-02","conditions":"Parkinson's Disease","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Madopar dispersible"],"phase":"marketed","status":"active","brandName":"Levodopa dispersible","genericName":"Levodopa dispersible","companyName":"Seoul National University Hospital","companyId":"seoul-national-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levodopa is converted to dopamine in the brain, replenishing dopamine levels depleted in Parkinson's disease. Used for Parkinson's disease (motor symptoms).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}